Home › Aortic Valve Insufficiency › NCT06780241
Novel Characterization of Sex Specific Biologic Signatures in Valvular Heart Disease
Who can join
Ages 18 to 90 · All sexes
Full eligibility criteria
Inclusion Criteria: * Age 18-90 years of age * Suspected moderate or severe (2-3+ or more) aortic regurgitation, or moderate or more aortic stenosis on the basis of prior known clinical history, echocardiogram or cardiac MRI. Exclusion Criteria: * Acute traumatic cardiac injury * Aortic dissection or aortic root rupture * Congenital heart diseases such as patent ductus arteriosus, coarctation of aorta, ASD and VSD * Presence of A-V fistula or intracardiac shunts * Any contraindications to cardiac MRI including: * Patients with any MR-incompatible implant, including cardiac pacemakers or defibrillators, or older types of cerebral aneurysm clips. * Patients who weigh more than 440 lbs. or have a very wide waist circumference. * Patients with claustrophobia may have difficulty tolerating the exam.
About the study
This project aims to validate sex-specific biologic signatures associated with aortic valve disease developed in a large multicenter CMR registry, using unsupervised phenomapping.
The aim to use standard and advanced CMR techniques (MRF, DTI, chemical exchange transfer, and radiomics analysis) is to determine advanced CMR predictors of reverse remodeling following aortic valve surgery and develop sex-specific thresholds for risk. Infrastructure developed by this study will enable development of an innovative, scalable, sex-specific precision medicine cardiovascular imaging pipeline to determine overall risk and treatment response.
What is being tested
- CMR (diagnostic test)
- Quality of Life Questionnaire (other)
Sponsor: The Cleveland Clinic · Participants: 200 · Started: Dec 10, 2024
Contact the study team
- Deborah Kwon, MD · Phone: 216-444-8526
Official record on ClinicalTrials.gov — NCT06780241
Locations in the U.S.
| Ohio | Cleveland Clinic, Cleveland |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.